Immunotherapy for Melanoma Cancer

A physician-evaluated, immune-based approach for patients diagnosed with melanoma — including advanced and metastatic cases.

Melanoma: Overview

Melanoma is one of the most aggressive forms of skin cancer. While early-stage melanoma can often be treated effectively, advanced or metastatic cases require more complex treatment strategies, including immunotherapy. Even with the availability of checkpoint inhibitors, not all patients respond as expected — or may experience progression over time.

NK Cell Immunotherapy offers a complementary, immune-based approach designed to support the body's natural ability to identify and respond to abnormal cells.

"Unlike adaptive immune therapies, NK cells do not require prior sensitization. This makes them especially relevant in cancers where immune evasion has already occurred."

Giostar Medical Team

Why early action is Critical

Melanoma can progress rapidly — especially in advanced stages. Delaying evaluation may limit available pathways.

Annual u.s. deaths

8,000+

deaths from melanoma annually in the United States. (cancer.org)

Skin cancer mortality

Majority of skin cancer deaths

caused by melanoma, despite representing fewer overall skin cancer cases.

Advanced Melanoma may spread to

Spread to lungs

Spread to brain

Spread to liver

Overall physical function

Although survival rates have improved with modern therapies, not all patients respond equally, and disease progression remains a major concern.

Why Consider Cellular Immunotherapy?

Natural Killer cells are part of the innate immune system and play a critical role in tumor surveillance. Unlike adaptive immune therapies, NK cells do not require prior sensitization to recognize abnormal cells — making them particularly relevant in cancers like melanoma, where immune evasion can occur and limit the effectiveness of other immunotherapies.

Nk cell mechanism

How Natural Killer Cells Target Cancer

Tumor Cell

Cancer cells evade normal immune detection

NK Recognition

NK cells detect "missing self" signals on abnormal cells

Cytotoxic Release

NK cells deploy perforin and granzymes

Cell Elimination

Tumor cell undergoes targeted aproptosis

In the clinical program, NK cells are collected from the patient, expanded in a controlled laboratory setting, and reinfused under physician oversight — supporting the body's own immune targeting capacity.

NK Cell Therapy is designed to:

Support innate immune response against tumor cells

Enhance immune surveillance

Provide a systemic, whole-body approach

Complement existing immunotherapy strategies when appropriate

Are You a Candidate?

NK Cell Immunotherapy may be considered for patients who:

Have been diagnosed with melanoma (any stage, subject to evaluation)

Have advanced or metastatic disease

Are exploring complementary or integrative treatment options

Have experienced limited response to immunotherapy or other treatments

Want to support immune function during or after treatment

Every case is individually reviewed by our physician team to determine eligibility.

Not all melanoma patients qualify for our program. Eligibility is determined individually through physician-led medical review. This page provides general educational context — not medical advice or a determination of suitability.

A Comprehensive Approach

Physician-led case review

In-house cellular laboratory processing

Nutritional support

International patient coordination

Clinical process

How the Process Works

Medical Evaluation

Your diagnosis, medical history, and treatment goals are reviewed by our physicians.

Immune Profiling & Blood Collection

A blood sample is collected to isolate immune cells and assess baseline function.

NK Cell Expansion

NK cells are activated and expanded in our specialized laboratory.

Controlled Reinfusion

Expanded NK cells are administered intravenously under clinical protocols.

Monitoring & Follow-Up

Progress is tracked through advanced laboratory testing and physician follow-up.

Next Step: Medical Review

If you or a family member has been diagnosed with breast cancer and is exploring additional options, the first step is to submit your case for physician review. Our team will assess your specific situation and respond with an eligibility determination.